A Phase 1, First-in-Human, Single-Dose, Open-Label, Positron Emission Tomography (PET) Imaging Study of [68Ga]MLN6907 in Patients With Metastatic Colorectal Carcinoma.

Trial Profile

A Phase 1, First-in-Human, Single-Dose, Open-Label, Positron Emission Tomography (PET) Imaging Study of [68Ga]MLN6907 in Patients With Metastatic Colorectal Carcinoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs Gallium 68 MLN 6907 (Primary)
  • Indications Colorectal cancer; Liver metastases
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 03 Jan 2017 Status changed from recruiting to completed.
    • 11 Jan 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
    • 18 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top